Aromatase inhibitors in early breast cancer treatment

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 14, 2003, Pages 46-57

  Mauriac, Louis ^a   Smith, Ian ^b  

^a INSTITUT BERGONIÉ   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; MA 17; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; ENDOMETRIUM CARCINOMA; ERYTHEMA MULTIFORME; FRACTURE; HOT FLUSH; HUMAN; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; MUSCULOSKELETAL DISEASE; MYALGIA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; WEIGHT GAIN;

EID: 0141650804     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00304-X     Document Type: Article

References (74)

1. Fisher B, Ravdin P, Ausman R, et al: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337-356, 1968
2. Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79:730-739, 1997
3. Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996
4. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
5. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001
6. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399-1411, 2000
7. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
8. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
9. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
10. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
11. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer (Cochrane review). The Cochrane Library, issue 2, Oxford: Updated software, 2002
12. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
13. National Institutes of Health: Adjuvant therapy for breast cancer. NIH Consensus Statement November 1-3. 17: 1-35, 2000
14. Gradishar W, Glusman J, Lu Y, et al: Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88:2047-2053, 2000
15. Robertson JF: ICI 182,780 (Fulvestrant) - The first oestrogen receptor down-regulator - Current clinical data. Br J Cancer 85:11-14, 2001 (suppl 2)
16. Holli K, Valavaara R, Blanco G, et al: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18:3487-3494, 2000
17. Buzdar AU, Come SE, Brodie A, et al: Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Summary consensus statement. Clin Cancer Res 7:4335s-4337s; discussion 4411s-4412s, 2001
18. Lohrisch C, Piccart M: Standard medical treatment for early breast cancer. Eur J Cancer 37:S45-S58, 2001 (suppl 7)
19. Mauriac L: Standards, options and recommendations for non metastatic breast cancer patients. Bull Cancer 89:207-224, 2002
20. Milla-Santos A, Milla L, Rallo L, et al: Phase III randomized trial of toremifene vs. tamoxifen in hormonodependent advanced breast cancer. Breast Cancer Res Treat 65:119-124, 2001
21. Demers LM: Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 30:95-102, 1994
22. Geisler J, King N, Dowsett M, et al: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286-1291, 1996
23. Kleeberg UR, Dowsett M, Carrion RP, et al: A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. Oncology 54:19-22, 1997 (suppl 2)
24. Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093, 1998
25. Baum M: Tamoxifen - The treatment of choice. Why look for alternatives? Br J Cancer 78:1-4, 1998 (suppl 4)
26. Edwards B, Howe H, Ries L, et al: Annual report to the Nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94:2766-2792, 2002
27. Newman LA, Mason J, Cote D, et al: African-American ethnicity, socioeconomic status, and breast cancer survival-A meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer 94:2844-2854, 2002
28. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4:459-471, 1986
29. Albain KS: Adjuvant chemotherapy and endocrine therapy for node-positive and node-negative breast carcinoma. Clin Obstet Gynecol 32:835-857, 1989
30. Koeppen HK, Wright BD, Burt AD, et al: Overexpression of HER2/neu in solid tumours: An immunohistochemical survey. Histopathology 38:96-104, 2001
31. Sjogren S, Inganas M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
32. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
33. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
34. Pinto AE, Andre S, Pereira T, et al: C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 12:525-533, 2001
35. Bezwoda WR: c-erb-B2 expression and response to treatment in metastatic breast cancer. Med Oncol 17:22-28, 2000
36. Houston SJ, Plunkett TA, Barnes DM, et al: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79:1220-1226, 1999
37. Tan A, Swain S: Adjuvant chemotherapy for breast cancer: An update. Semin Oncol 28:359-376, 2001
38. Dewar J, Horobin J, Preece P, et al: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305:225-226, 1992
39. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
40. Powles T, Hickish T, Kanis J, et al: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
41. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14:2000-2011, 1996
42. Dirix LY, Piccart MJ, Lohrisch C, et al: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 20:29a, 2001 (abstr 114)
43. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialist's Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
44. Buzdar A: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - Update efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 77:295, 2003
45. Goss PE: Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res 7:4397s-4401s; discussion 4411s-4412s, 2001
46. Mamounas EP: Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology (Huntingt) 15:35-39, 2001
47. Langer AS: Side effects, quality-of-life issues, and trade-offs: the patient perspective. J Natl Cancer Inst Monogr 30: 125-129, 2001
48. Chauvergne J, Durand M, Hoemi B, et al: Induction chemotherapy in high risk breast cancer. Results of a prospective therapeutic study (author's translation). Bull Cancer 66: 9-16, 1979
49. Schick P, Goodstein J, Moor J, et al: Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 22:278-282, 1983
50. Leichman L, Steiger Z, Seydel HG, et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach. J Clin Oncol 2:75-79, 1984
51. Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-1230, 1982
52. Perloff M, Lesnick GJ: Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 117:879-881, 1982
53. Schuller DE, Wilson HE, Smith RE, et al: Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer 51:15-19, 1983
54. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
55. Jacquillat C, Weil M, Baillet F, et al: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66:119-129, 1990
56. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347-354, 1991
57. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 30A:645-652, 1994
58. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
59. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
60. Makris A, Powles TJ, Ashley SE, et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184, 1998
61. van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
62. Mauriac L, MacGrogan G, Avril A, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47-52, 1999
63. Semiglazov VF, Topuzov EE, Bavli JL, et al: Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5:591-595, 1994
64. Robertson JF, Ellis IO, Elston CW, et al: Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 28A:908-910, 1992
65. Gazet JC, Ford HT, Coombes RC, et al: Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20:207-214, 1994
66. Bates T, Riley DL, Houghton J, et al: Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 78:591-594, 1991
67. Mustacchi G, Milani S, Pluchinotta A, et al: Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 14:2197-2200, 1994
68. Miller WR, Anderson TJ, Hawkins RA, et al: Neoadjuvant endocrine treatment: The Edinburgh Experience, in Howell A, Dowsett M (eds): ESO Scientific Updates (vol 4). Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects. Amsterdam, Elsevier Science, 1999, pp 89-99
69. Mauriac L, Debled M, Durand M, et al: Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 13:293-298, 2002
70. Dixon JM, Love CD, Bellamy CO, et al: Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66:191-199, 2001
71. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
72. Miller WR, Dixon JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9:9-15, 2002
73. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
74. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001